<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">oncotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский онкологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian journal of oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1814-4861</issn><issn pub-type="epub">2312-3168</issn><publisher><publisher-name>Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21294/1814-4861-2020-19-2-41-48</article-id><article-id custom-type="elpub" pub-id-type="custom">oncotomsk-1397</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Клиническая значимость Р16-позитивного статуса и высокой пролиферативной активности у пациентов с орофарингеальной плоскоклеточной карциномой</article-title><trans-title-group xml:lang="en"><trans-title>Clinical significance of P16-positive status and high index of proliferative activity in patients with oropharyngeal squamous cell carcinoma</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0698-7710</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Стукань</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Stukan</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Стукань Анастасия Игоревна - врач-онколог, КОД № 1, SPIN-код: 9155-6715. AuthorID (РИНЦ): 1025660. Researcher ID (WOS): E-5524-2019.</p><p>350040, Краснодар, ул. Димитрова, 146; 350063, Краснодар, ул. Митрофана Седина, 43</p></bio><bio xml:lang="en"><p>Anastasia I Stukan - oncologist, CDO. Researcher ID (WOS): E-5524-2019. ORCID: 0000-0002-0698-7710.</p><p>146, Dimitrova Street, 350040-Krasnodar; 4, Mitrofana sedina street, 350063-Krasnodar</p></bio><email xlink:type="simple">jolie86@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0572-1395</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Порханов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Porkhanov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Порханов Владимир Алексеевич - доктор медицинских наук, профессор, академик РАН, главный врач НИИ – КрКБ № 1; заведующий кафедрой онкологии с курсом торакальной хирургии, КГМУ. SPIN-код: 2446-5933. AuthorID (РИНЦ): 682896. Researcher ID (WOS): O-9470-2017.</p><p>350086, Краснодар, ул. 1 Мая, 1672; 350063, Краснодар, ул. Митрофана Седина, 43</p></bio><bio xml:lang="en"><p>Vladimir A. Porkhanov, DSc, Professor, Academician RAS, Head of Scientific Investigational Institute State Clinical Hospital № 1 named by professor S.V Ochapovsky; Head of Department of Oncology with Course of Thoracic Surgery of KSMU. Researcher ID (WOS): O-9470-2017.</p><p>167, May 1 street, 350086-Krasnodar; 4, Mitrofana sedina street, 350063-Krasnodar</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3169-9558</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бодня</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Bodnya</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бодня Вадим Николаевич - доктор медицинских наук, доцент кафедры онкологии с курсом торакальной хирургии, КГМУ. SPIN-код: 8506-1987. AuthorID (РИНЦ): 740756. Researcher ID (WOS): F-2670-2019.</p><p>350063, Краснодар, ул. Митрофана Седина, 43</p></bio><bio xml:lang="en"><p>Vadim N. Bodnya - DSc, Department of Oncology with Course of Thoracic Surgery of KSMU. Researcher ID (WOS): F-2670-2019. ORCID: 0000-0003-3169-9558.</p><p>4, Mitrofana sedina street, 350063-Krasnodar</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ГБУЗ «Клинический онкологический диспансер №1» Министерства здравоохранения Краснодарского края; ФГБОУ ВО «Кубанский государственный медицинский университет» Министерства здравоохранения Российской Федерации<country>Россия</country></aff><aff xml:lang="en">Clinical Dispensary of Oncology; Kuban state Medical University<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ГБУЗ «Научно-исследовательский институт - Краевая клиническая больница № 1 им. профессора С.В. Очаповского» Министерства здравоохранения Краснодарского края; ФГБОУ ВО «Кубанский государственный медицинский университет» Министерства здравоохранения Российской Федерации<country>Россия</country></aff><aff xml:lang="en">Scientific Investigational Institute State Clinical Hospital № 1 named by professor S.V. Ochapovsky; Kuban state Medical University<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">ФГБОУ ВО «Кубанский государственный медицинский университет» Министерства здравоохранения Российской Федерации<country>Россия</country></aff><aff xml:lang="en">Kuban state Medical university<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>28</day><month>04</month><year>2020</year></pub-date><volume>19</volume><issue>2</issue><fpage>41</fpage><lpage>48</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Стукань А.И., Порханов В.А., Бодня В.Н., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Стукань А.И., Порханов В.А., Бодня В.Н.</copyright-holder><copyright-holder xml:lang="en">Stukan A.I., Porkhanov V.A., Bodnya V.N.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.siboncoj.ru/jour/article/view/1397">https://www.siboncoj.ru/jour/article/view/1397</self-uri><abstract><sec><title>Введение</title><p>Введение. По классификации TNM UICC/AJCC 8-го пересмотра предлагается разделить орофарингеальную плоскоклеточную карциному на 2 молекулярных подтипа по ВПЧ-статусу с различными клиническими и прогностическими характеристиками ввиду биологических особенностей. Так, имеются отличия в подходах к стадированию орофарингеального рака, и в будущем это приведет к реализации профилактических мероприятий и внедрению новых терапевтических стратегий в отношении ВПЧ-позитивного рака.</p><p>Цель исследования - оценить клинико-прогностическую значимость комбинации суррогатного маркера ВПЧ-позитивного статуса P16 с высокой пролиферативной активностью при орофарингеальном раке.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Иммуногистохимический анализ выполнен с моноклональными антителами к P16 и Ki67 на срезах с парафиновых гистоблоков опухолевых образцов 104 больных плоскоклеточным раком языка и ротоглотки, проходивших лечение в ГБУЗ КОД № 1 г Краснодара в 2011-16 гг Р16-положительный статус определяли при умеренном или сильном ядерном и цитоплазматическом окрашивании более 70 % опухолевых клеток. Высокий индекс пролиферативной активности устанавливался, если более 50 % опухолевых клеток имели ядерное окрашивание антигена Ki67.</p></sec><sec><title>Результаты</title><p>Результаты. Р16-позитивный статус был связан с раком нёбных миндалин (р=0,002), характерен для женщин (р=0,015), ассоциирован с возрастом моложе 60 лет (р&lt;0,001), морфологией без ороговения (р=0,022), высокой пролиферацией (р=0,01). Сочетание Р16-позитивного статуса с высокой пролиферацией продемонстрировало корреляцию с раком нёбных миндалин (р&lt;0,001), женским полом (р=0,015), возрастом моложе 60 лет (р&lt;0,001) и морфологией без ороговения (р=0,012). ВПЧ-позитивные больные и пациенты с комбинацией Р16-позитивного статуса и высокого индекса пролиферативной активности с метастазами лимфатических узлов (N1-2) имели более высокие показатели 3-летней общей выживаемости (p=0,021).</p></sec><sec><title>Вывод</title><p>Вывод. Корреляция ИГХкомплекса Р16-позитивности и высокой пролиферативной активности с клинико-морфологическими особенностями и общей выживаемостью подтверждает особенности биологии ВПЧ-ассоциированного рака. Исследование комбинации индекса пролиферативной активности в дополнение к суррогатному маркеру ВПЧ-статуса приведет к повышению диагностической точности ИГХ-анализа ВПЧ-статуса и позволит определять прогноз пациентов с плоскоклеточным раком головы и шеи.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. In accordance with uICC and AJCC 8th edition TNM classifications, there is a strong evidence for division of oropharyngeal squamous cell carcinoma (OPSCC) into 2 molecular subtypes by HPV-status with distinct prognosis depending on biological differences. Such a division leads to differences in staging OPSCC and in future it will lead to implementation of preventive measures and new therapeutic strategies against HPV-positive cancer.</p></sec><sec><title>Aim of the study</title><p>Aim of the study: to assess the clinical and prognostic significance of the combination of P16, a surrogate marker for HPV-positivity, and high proliferative activity in patients with oropharyngeal carcinoma.</p></sec><sec><title>Material and Methods</title><p>Material and Methods. Immunohistochemical (ICH) analysis with monoclonal antibodies specific for P16 and Ki67 proteins was used to detect expression patterns in the formalin-fixed, paraffin-embedded tumor samples obtained from 104 patients with squamous cell carcinoma of the tongue and oropharynx, treated at Oncological Dispencery № 1 in Krasnodar from 2011 to 2016. HPV-positive status was determined if more than 70 % of tumor cells had moderate or strong nuclear and cytoplasmic P16-staining. High index of proliferative activity (PA) was detected if more than 50 % tumor cells expressed Ki67 nuclear antigen.</p></sec><sec><title>Results</title><p>Results. P16-positivie status was associated with tonsillar cancer (р=0.002), female gender (р=0.015), age &lt;60 years (р&lt;0.001), non - keratinizing morphology (р=0.022), and high index of PA (p=0.01).The combination of P16&gt;70 % with high PA demonstrated correlation with tonsillar cancer (р&lt;0.001), female gander (р=0.015), age under 60 years (р&lt;0.001) and non - keratinizing morphology (р=0.012). HPV-positive patients and patients with a combination of P16&gt;70 % and high index of PA at N1-2 had an overall survival benefit (p=0.021).</p></sec><sec><title>Conclusion</title><p>Conclusion. The correlation between IHC-complex for P16&gt;70 %/Ki67&gt;50 % and clinicopathologicl parameters and overall survival confirms the biological features of HPV-associated cancer. The evaluation of this IHC-complex can increase the diagnostic accuracy of IHC-analysis of HPV-status and predict the prognosis of patients with OPSCC.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рак головы и шеи</kwd><kwd>плоскоклеточная карцинома</kwd><kwd>вирус папилломы человека</kwd><kwd>P16INK4a-экспрессия</kwd><kwd>Ki67</kwd></kwd-group><kwd-group xml:lang="en"><kwd>head and neck cancer</kwd><kwd>squamous cell carcinoma</kwd><kwd>human papillomavirus</kwd><kwd>P16INK4a-expression</kwd><kwd>Ki67-expression</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015 Jan 29; 517(7536): 576-82. doi: 10.1038/nature14129.</mixed-citation><mixed-citation xml:lang="en">The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015 Jan 29; 517(7536): 576-82. doi: 10.1038/nature14129.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">GallowayD.A., LaiminsL.A. Human papillomaviruses: shared and distinct pathways for pathogenesis. Curr Opin Virol. 2015 Oct; 14: 87-92. doi: 10.1016/j.coviro.2015.09.001.</mixed-citation><mixed-citation xml:lang="en">GallowayD.A., LaiminsL.A. Human papillomaviruses: shared and distinct pathways for pathogenesis. Curr Opin Virol. 2015 Oct; 14: 87-92. doi: 10.1016/j.coviro.2015.09.001.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">КапринА.Д., СтаринскийВ.В., ПетроваГ.В. Состояние онкологической помощи в России в 2018 году. М., 2019. 250 с.</mixed-citation><mixed-citation xml:lang="en">Kaprin A.D., Starinckiy V.V., Petrova G.V The state of cancer care in Russia in 2018. Moscow; 2019. 250 p. (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Jiron J., Sethi S., Ali-Fehmi R., Franceschi S., Struijk L., van Doorn L.J., Quint W., Kato I. Racial disparities in Human Papillomavirus(HPV) associated head and neck cancer. Am J Otolaryngol. 2014 Mar-Apr; 35(2): 147-53. doi: 10.1016/j.amjoto.2013.09.004.</mixed-citation><mixed-citation xml:lang="en">Jiron J., Sethi S., Ali-Fehmi R., Franceschi S., Struijk L., van Doorn L.J., Quint W., Kato I. Racial disparities in Human Papillomavirus(HPV) associated head and neck cancer. Am J Otolaryngol. 2014 Mar-Apr; 35(2): 147-53. doi: 10.1016/j.amjoto.2013.09.004.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Черемисина О.В., Чойнзонов Е.Л., Панкова О.В., Мухамедов М.Р., УразоваЛ.Н., Дворянинова О.Ю. Папилломатоз как критерий формирования группы риска по раку гортани. Вестник оториноларингологии. 2015; 80(1): 39-43.</mixed-citation><mixed-citation xml:lang="en">Cheremisina O.V, Choinzonov E.L., Pankova O.V., MukhamedovM.R., UrazovaL.N., Dvorianinova O.Yu. Papillomatosis as a criteria for the formation of the group at risk of laryngeal cancer. Bulletin Otorinolaringology. 2015; 80(1): 39-43. (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Grоnhоj L.C., Gylden^ve M., Jensen D.H., Therkildsen M.H., Kiss K., Norrild B., Konge L., von Buchwald C. Correlation between human papillomavirus and P16 overexpression in oropharyngeal tumours: a systematic review. Br J Cancer. 2014 Mar 18; 110(6): 1587-94. doi: 10.1038/bjc.2014.42.</mixed-citation><mixed-citation xml:lang="en">Grоnhоj L.C., Gylden^ve M., Jensen D.H., Therkildsen M.H., Kiss K., Norrild B., Konge L., von Buchwald C. Correlation between human papillomavirus and P16 overexpression in oropharyngeal tumours: a systematic review. Br J Cancer. 2014 Mar 18; 110(6): 1587-94. doi: 10.1038/bjc.2014.42.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Galloway D.A., Laimins L.A. Human papillomaviruses: shared and distinct pathways for pathogenesis. Curr Opin Virol. 2015 Oct; 14: 87-92. doi: 10.1016/j.coviro.2015.09.001.</mixed-citation><mixed-citation xml:lang="en">Galloway D.A., Laimins L.A. Human papillomaviruses: shared and distinct pathways for pathogenesis. Curr Opin Virol. 2015 Oct; 14: 87-92. doi: 10.1016/j.coviro.2015.09.001.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z., Xia R.H., Ye D.X., Li J. Human Papillomavirus 16 Infection and TP53 Mutation: Two Distinct Pathogeneses for Oropharyngeal Squamous Cell Carcinoma in an Eastern Chinese Population. PLoS One. 2016 Oct 17; 11(10): e0164491. doi: 10.1371/journal.pone.0164491.</mixed-citation><mixed-citation xml:lang="en">Wang Z., Xia R.H., Ye D.X., Li J. Human Papillomavirus 16 Infection and TP53 Mutation: Two Distinct Pathogeneses for Oropharyngeal Squamous Cell Carcinoma in an Eastern Chinese Population. PLoS One. 2016 Oct 17; 11(10): e0164491. doi: 10.1371/journal.pone.0164491.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">JohnsonM.E., CantalupoP.G., Pipas J.M. Identification of head and neck cancer subtypes based on human papillomavirus presence and E2F-regulated gene expression. mSphere. 2018 Jan 10; 3(1). pii: e00580-17. doi: 10.1128/mSphere.00580-17.</mixed-citation><mixed-citation xml:lang="en">JohnsonM.E., CantalupoP.G., Pipas J.M. Identification of head and neck cancer subtypes based on human papillomavirus presence and E2F-regulated gene expression. mSphere. 2018 Jan 10; 3(1). pii: e00580-17. doi: 10.1128/mSphere.00580-17.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Huang S.H., O'Sullivan B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Curr Treat Options Oncol. 2017 Jul; 18(7): 40. doi: 10.1007/s11864-017-0484-y.</mixed-citation><mixed-citation xml:lang="en">Huang S.H., O'Sullivan B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Curr Treat Options Oncol. 2017 Jul; 18(7): 40. doi: 10.1007/s11864-017-0484-y.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">PriggeE.S., ArbynM., vonKnebelDoeberitz M., ReuschenbachM. Diagnostic accuracy of P16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: a systematic review and meta-analysis. Int J Cancer. 2017 Mar 1; 140(5): 1186-98. doi: 10.1002/ijc.30516.</mixed-citation><mixed-citation xml:lang="en">PriggeE.S., ArbynM., vonKnebelDoeberitz M., ReuschenbachM. Diagnostic accuracy of P16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: a systematic review and meta-analysis. Int J Cancer. 2017 Mar 1; 140(5): 1186-98. doi: 10.1002/ijc.30516.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis J.S.Jr. P16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2012 Jul; 6 Suppl 1: S75-82. doi: 10.1007/s12105-012-0369-0.</mixed-citation><mixed-citation xml:lang="en">Lewis J.S.Jr. P16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2012 Jul; 6 Suppl 1: S75-82. doi: 10.1007/s12105-012-0369-0.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis J.S.Jr., Beadle B., Bishop J.A., ChernockR.D., Colasacco C., Lacchetti C., Moncur J.T., Rocco J.W., Schwartz M.R., Seethala R.R., Thomas N.E., Westra W.H., Faquin W.C. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. Arch Pathol Lab Med. 2018 May; 142(5): 559-97. doi: 10.5858/arpa.2017-0286-CP</mixed-citation><mixed-citation xml:lang="en">Lewis J.S.Jr., Beadle B., Bishop J.A., ChernockR.D., Colasacco C., Lacchetti C., Moncur J.T., Rocco J.W., Schwartz M.R., Seethala R.R., Thomas N.E., Westra W.H., Faquin W.C. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. Arch Pathol Lab Med. 2018 May; 142(5): 559-97. doi: 10.5858/arpa.2017-0286-CP</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Mielcarek-Kuchta D., Olofsson J., Golusinski W. p53, Ki67 and cyclin D1 as prognostic factors of lymph node metastases in laryngeal carcinoma. Eur Arch Otorhinolaryngol. 2003; 260(10): 549-54. doi: 10.1007/s00405-003-0651-6.</mixed-citation><mixed-citation xml:lang="en">Mielcarek-Kuchta D., Olofsson J., Golusinski W. p53, Ki67 and cyclin D1 as prognostic factors of lymph node metastases in laryngeal carcinoma. Eur Arch Otorhinolaryngol. 2003; 260(10): 549-54. doi: 10.1007/s00405-003-0651-6.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
